RA0352

antibody from Oursmab

Targeting: IL17RA CD217, CDw217, hIL-17R, IL-17RA, IL17R

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0352

Provider

Oursmab

Product name

Brodalumab (Biosimilar Reference Antibody) (IL17RA)

Antibody type

Monoclonal

Description

Brodalumab is a fully human monoclonal antibody used in the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. It was first approved for medical use in 2017 and is marketed under the brand name Siliq? in the United States and Kyntheum? in the European Union. As an interleukin-17 receptor antagonist, brodalumab works by binding to and blocking the activity of a specific inflammatory pathway. While highly effective, its prescribing information includes a Boxed Warning¡ªthe most serious type of FDA warning¡ªdue to an observed risk of suicidal ideation and behavior, requiring specific risk evaluation and mitigation strategies (REMS).

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Brodalumab (Biosimilar Reference Antibody) (IL17RA)-RA0352-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Brodalumab (Biosimilar Reference Antibody) (IL17RA)-RA0352 in a linear range of 3.91-125 ng/mL.